NervGen Pharma Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGENF research report →
About the company
NervGen Pharma Corp. , including its affiliated entities, is focused on discovering, advancing, and bringing to market pharmaceutical solutions designed to address medical conditions arising from damage to the nervous system. Their primary experimental compound, NVG-291, is currently undergoing Phase 1 clinical trials to assess its potential effectiveness for spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease.
- CEO
- Adam H. Rogers
- IPO
- 2019
- Employees
- 11
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $312.89M
- P/E
- -8.41
- P/S
- 0.00
- P/B
- 108.37
- EV/EBITDA
- -15.42
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -17536.81%
- ROIC
- -719.57%
- Revenue
- $0 · 0.00%
- Net Income
- $-24,005,895 · -7.25%
- EPS
- $-0.36 · 5.26%
- Op Income
- $-24,931,994
- FCF YoY
- -47.25%
- 52W High
- $6.30
- 52W Low
- $1.50
- 50D MA
- $4.41
- 200D MA
- $3.11
- Beta
- 0.76
- Avg Volume
- 157.91K
Get TickerSpark's AI analysis on NGENF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NGENF coverage
Recent articles, reports, and earnings notes.
No research on NGENF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NGENF report →Similar companies
Peers in the same neighborhood.